Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 14 studies | 35% ± 19% | |
| peripheral blood | 12 studies | 24% ± 8% | |
| lung | 8 studies | 23% ± 5% | |
| eye | 6 studies | 22% ± 10% | |
| liver | 5 studies | 26% ± 11% | |
| bone marrow | 4 studies | 22% ± 4% | |
| kidney | 4 studies | 20% ± 2% | |
| adipose | 4 studies | 23% ± 2% | |
| heart | 3 studies | 21% ± 3% | |
| lymph node | 3 studies | 18% ± 1% | |
| intestine | 3 studies | 22% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 3234.58 | 1445 / 1445 | 100% | 26.88 | 183 / 183 |
| lung | 100% | 4022.54 | 578 / 578 | 100% | 21.44 | 1155 / 1155 |
| breast | 100% | 3989.92 | 459 / 459 | 100% | 27.47 | 1115 / 1118 |
| prostate | 100% | 3133.97 | 245 / 245 | 100% | 16.63 | 500 / 502 |
| bladder | 100% | 3597.76 | 21 / 21 | 99% | 16.81 | 501 / 504 |
| uterus | 100% | 3947.32 | 170 / 170 | 99% | 17.09 | 455 / 459 |
| intestine | 100% | 3464.21 | 966 / 966 | 99% | 16.41 | 522 / 527 |
| stomach | 100% | 2438.43 | 359 / 359 | 99% | 17.42 | 283 / 286 |
| thymus | 100% | 3304.16 | 653 / 653 | 99% | 16.60 | 598 / 605 |
| ovary | 100% | 3840.94 | 180 / 180 | 99% | 16.77 | 424 / 430 |
| pancreas | 100% | 1793.90 | 327 / 328 | 99% | 18.35 | 176 / 178 |
| skin | 100% | 5819.79 | 1809 / 1809 | 97% | 20.99 | 456 / 472 |
| kidney | 100% | 2079.79 | 89 / 89 | 95% | 15.11 | 854 / 901 |
| brain | 95% | 1255.32 | 2503 / 2642 | 100% | 15.57 | 702 / 705 |
| adrenal gland | 100% | 3915.48 | 258 / 258 | 90% | 9.83 | 207 / 230 |
| liver | 100% | 1614.96 | 226 / 226 | 82% | 7.66 | 331 / 406 |
| adipose | 100% | 3923.77 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 3469.86 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 19.62 | 29 / 29 |
| spleen | 100% | 4349.59 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 22.42 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 5.13 | 1 / 1 |
| muscle | 99% | 1701.21 | 797 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 99% | 4280.75 | 918 / 929 | 0% | 0 | 0 / 0 |
| heart | 95% | 1718.45 | 815 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 88% | 9.65 | 70 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0006338 | Biological process | chromatin remodeling |
| GO_0032922 | Biological process | circadian regulation of gene expression |
| GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
| GO_0140718 | Biological process | facultative heterochromatin formation |
| GO_0006355 | Biological process | regulation of DNA-templated transcription |
| GO_0051090 | Biological process | regulation of DNA-binding transcription factor activity |
| GO_0005730 | Cellular component | nucleolus |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0000785 | Cellular component | chromatin |
| GO_0005634 | Cellular component | nucleus |
| GO_0035064 | Molecular function | methylated histone binding |
| GO_0003677 | Molecular function | DNA binding |
| GO_0004857 | Molecular function | enzyme inhibitor activity |
| GO_0042393 | Molecular function | histone binding |
| GO_0000976 | Molecular function | transcription cis-regulatory region binding |
| GO_0034647 | Molecular function | histone H3K4me/H3K4me2/H3K4me3 demethylase activity |
| GO_0032452 | Molecular function | histone demethylase activity |
| GO_0008270 | Molecular function | zinc ion binding |
| GO_0031490 | Molecular function | chromatin DNA binding |
| GO_0003713 | Molecular function | transcription coactivator activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | KDM5A |
| Protein name | Lysine-specific demethylase 5A (EC 1.14.11.67) (Histone demethylase JARID1A) (Jumonji/ARID domain-containing protein 1A) (Retinoblastoma-binding protein 2) (RBBP-2) ([histone H3]-trimethyl-L-lysine(4) demethylase 5A) Lysine-specific demethylase 5A Lysine demethylase 5A |
| Synonyms | JARID1A RBP2 RBBP2 |
| Description | FUNCTION: Histone demethylase that specifically demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9', H3 'Lys-27', H3 'Lys-36', H3 'Lys-79' or H4 'Lys-20'. Demethylates trimethylated and dimethylated but not monomethylated H3 'Lys-4'. Regulates specific gene transcription through DNA-binding on 5'-CCGCCC-3' motif . May stimulate transcription mediated by nuclear receptors. Involved in transcriptional regulation of Hox proteins during cell differentiation . May participate in transcriptional repression of cytokines such as CXCL12. Plays a role in the regulation of the circadian rhythm and in maintaining the normal periodicity of the circadian clock. In a histone demethylase-independent manner, acts as a coactivator of the CLOCK-BMAL1-mediated transcriptional activation of PER1/2 and other clock-controlled genes and increases histone acetylation at PER1/2 promoters by inhibiting the activity of HDAC1 (By similarity). Seems to act as a transcriptional corepressor for some genes such as MT1F and to favor the proliferation of cancer cells . . |
| Accessions | F5GZR8 ENST00000543507.1 ENST00000536014.5 ENST00000544760.1 ENST00000399788.7 [P29375-1] P29375 F5H322 E7EV89 F5GZ99 A0A6B9SM32 ENST00000535014.5 |